Xeris Biopharma Holdings Inc Revenue Growth Rates (XERS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Xeris Biopharma Holdings Inc   (NASDAQ: XERS)
 

XERS's Revenue Growth by Quarter and Year

Xeris Biopharma Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

XERS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 92.10
1st Quarter March 83.13
FY 175.23

XERSs Annual Revenue
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2025 $ 291.85 millions
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2024 $ 203.07 millions
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2023 $ 163.91 millions
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2022 $ 110.25 millions
Xeris Biopharma Holdings Inc 's Revenue in the fiscal year 2021 $ 49.59 millions




XERS Revenue second quarter 2026 Y/Y Growth Comment
Xeris Biopharma Holdings Inc reported Revenue improvement of 28.74% year on year in the second quarter 2026, to $ 92.10 millions, this is lower than Xeris Biopharma Holdings Inc 's recent average Revenue surge of 5151.14%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 74 other companies have achieved higher Revenue growth. While Xeris Biopharma Holdings Inc ' s Revenue rise of 28.74% ranks overall at the positon no. 764 in the second quarter 2026.


XERS Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 42.78 % 35.39 % 33.95 %
3rd Quarter September - 37.06 % 12.31 % 62.53 %
2nd Quarter June 28.74 % 48.82 % 26.47 % 50.18 %
1st Quarter March 38.27 % 47.93 % 22.41 % 50.43 %
FY   - 43.71 % 23.89 % -

Financial Statements
Xeris Biopharma Holdings Inc 's second quarter 2026 Revenue $ 92.10 millions XERS's Income Statement
Xeris Biopharma Holdings Inc 's second quarter 2025 Revenue $ 71.54 millions Quarterly XERS's Income Statement


XERS Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 15.37 % 10.74 % -8.13 %
3rd Quarter September - 3.97 % 12.9 % 27.12 %
2nd Quarter June 10.79 % 19 % 18.28 % 14.49 %
1st Quarter March -3.12 % 0.03 % -8.45 % 0.18 %
FY (Year on Year)   - 43.71 % 23.89 % -


Back to XERS Growth rate Comparisons >> Back to XERS Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #75
Healthcare Sector #166
Overall #764

Revenue Y/Y Growth Statistics
High Average Low
104877.78 % 5151.14 % -100 %
(Dec 31 2020)   (Sep 30 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #75
Healthcare Sector #166
Overall #764
Revenue Y/Y Growth Statistics
High Average Low
104877.78 % 5151.14 % -100 %
(Dec 31 2020)   (Sep 30 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Xeris Biopharma Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
17444.44 % 557.88 % -100 %
(Dec 31 2019)  


XERS's II. Quarter Q/Q Revenue Comment
Xeris Biopharma Holdings Inc achieved in the II. Quarter 2026 below company average Revenue rise of 10.79% quarter on quarter, to $ 92.10 millions.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Xeris Biopharma Holdings Inc 's Revenue growth quarter on quarter, overall rank is 771.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #771
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #771
Revenue Q/Q Growth Statistics
High Average Low
17444.44 % 557.88 % -100 %
(Dec 31 2019)  


XERS's II. Quarter Q/Q Revenue Comment
Xeris Biopharma Holdings Inc achieved in the II. Quarter 2026 below company average Revenue rise of 10.79% quarter on quarter, to $ 92.10 millions.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Xeris Biopharma Holdings Inc 's Revenue growth quarter on quarter, overall rank is 771.


Xeris Biopharma Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 335.41 $ 314.85 $ 291.85 $ 266.14 $ 246.03
Y / Y Revenue Growth (TTM) 36.33 % 41.47 % 43.72 % 42.05 % 35.62 %
Year on Year Revenue Growth Overall Ranking # 479 # 458 # 284 # 318 # 298
Seqeuential Revenue Change (TTM) 6.53 % 7.88 % 9.66 % 8.17 % 10.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 1442 # 1333 # 869 # 1249 # 1010


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Xeris Biopharma Holdings Inc 's cumulative twelve months Revenue were $ 335 millions, company would post below average annual Revenue growth of 10.55% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Xeris Biopharma Holdings Inc 's Revenue growth from the 83.13% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 458 to 479.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 114
Overall # 479

Revenue TTM Y/Y Growth Statistics
High Average Low
15523.16 %
 806.96 %
22.72 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 244
S&P 500 # 1442
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Xeris Biopharma Holdings Inc 's cumulative twelve months Revenue were $ 335 millions, company would post below average annual Revenue growth of 22.72% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Xeris Biopharma Holdings Inc 's Revenue growth from the 83.13% growth in Mar 31 2026.

In the Healthcare sector 113 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 458 to 479.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 114
Overall # 479

Revenue TTM Y/Y Growth Statistics
High Average Low
15523.16 %
806.96 %
22.72 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 81
Sector # 244
S&P 500 # 1442




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XERS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions


About Xeris Biopharma Holdings Inc Revenue Growth Rates (XERS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.